CDKN2A and cancer: Repression of human ARF expression is a relatively common mechanism by which cancers can evade this tumor suppressor activity [47]; presumably, restoring ARF expression could represent a novel therapeutic approach, especially for that subset of cancers also retaining wild type p53.